Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter

Stuart J Connolly; Harry J G M Crijns; Christian Torp-Pedersen; Martin van Eickels; Christophe Gaudin; Richard L Page; Stefan H Hohnloser; ATHENA Investigators

doi:10.1161/CIRCULATIONAHA.109.875252

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter

Stuart J Connolly, Harry J G M Crijns, Christian Torp-Pedersen, Martin van Eickels, Christophe Gaudin, Richard L Page, Stefan H Hohnloser, ATHENA Investigators

229 Citationer (Scopus)

Abstract

Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter).

Originalsprog	Engelsk
Tidsskrift	Circulation (Baltimore)
Vol/bind	120
Udgave nummer	13
Sider (fra-til)	1174-80
Antal sider	7
ISSN	0009-7322
DOI	https://doi.org/10.1161/CIRCULATIONAHA.109.875252
Status	Udgivet - 29 sep. 2009

Adgang til dokumentet

10.1161/CIRCULATIONAHA.109.875252

Fingeraftryk

Dyk ned i forskningsemnerne om 'Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Connolly, S. J., Crijns, H. J. G. M., Torp-Pedersen, C., van Eickels, M., Gaudin, C., Page, R. L., Hohnloser, S. H., & ATHENA Investigators (2009). Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation (Baltimore), 120(13), 1174-80. https://doi.org/10.1161/CIRCULATIONAHA.109.875252

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. / Connolly, Stuart J; Crijns, Harry J G M; Torp-Pedersen, Christian et al.
I: Circulation (Baltimore), Bind 120, Nr. 13, 29.09.2009, s. 1174-80.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Connolly, SJ, Crijns, HJGM, Torp-Pedersen, C, van Eickels, M, Gaudin, C, Page, RL, Hohnloser, SH & ATHENA Investigators 2009, 'Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter', Circulation (Baltimore), bind 120, nr. 13, s. 1174-80. https://doi.org/10.1161/CIRCULATIONAHA.109.875252

Connolly SJ, Crijns HJGM, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation (Baltimore). 2009 sep. 29;120(13):1174-80. doi: 10.1161/CIRCULATIONAHA.109.875252

Connolly, Stuart J ; Crijns, Harry J G M ; Torp-Pedersen, Christian et al. / Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. I: Circulation (Baltimore). 2009 ; Bind 120, Nr. 13. s. 1174-80.

@article{46de249c1a8847c39c47f1d6272e076b,

title = "Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter",

abstract = "Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter).",

author = "Connolly, {Stuart J} and Crijns, {Harry J G M} and Christian Torp-Pedersen and {van Eickels}, Martin and Christophe Gaudin and Page, {Richard L} and Hohnloser, {Stefan H} and {ATHENA Investigators}",

year = "2009",

month = sep,

day = "29",

doi = "10.1161/CIRCULATIONAHA.109.875252",

language = "English",

volume = "120",

pages = "1174--80",

journal = "Circulation (Baltimore)",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "13",

}

TY - JOUR

T1 - Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter

AU - Connolly, Stuart J

AU - Crijns, Harry J G M

AU - Torp-Pedersen, Christian

AU - van Eickels, Martin

AU - Gaudin, Christophe

AU - Page, Richard L

AU - Hohnloser, Stefan H

AU - ATHENA Investigators

PY - 2009/9/29

Y1 - 2009/9/29

N2 - Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter).

AB - Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter).

U2 - 10.1161/CIRCULATIONAHA.109.875252

DO - 10.1161/CIRCULATIONAHA.109.875252

M3 - Journal article

C2 - 19752319

SN - 0009-7322

VL - 120

SP - 1174

EP - 1180

JO - Circulation (Baltimore)

JF - Circulation (Baltimore)

IS - 13

ER -